Robert J. Weiland
Insider
First SEC filing: May 4, 2016 · Latest: May 4, 2016
Insider at
Insider transactions
0 buys (P)
0 sells (S)
Net: $0
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| June 4, 2018 | PCRX | S | 373 | $33.02 | $12,316 | 5,088 Direct | -6.83% | Disposed | -23.7% (price as of 2026-10-02) |
| June 14, 2017 | PCRX | A | 4,500 | · | · | 4,864 Direct | +1236.26% | Acquired | (price as of 2026-10-02) |
| June 14, 2017 | PCRX | A | 9,000 | · | · | 9,000 Direct | · | Acquired | (price as of 2026-10-02) |
| Dec. 7, 2016 | PCRX | A | 16,000 | · | · | 16,000 Direct | · | Acquired | (price as of 2026-10-02) |
| June 15, 2016 | PCRX | A | 10,000 | · | · | 10,000 Direct | · | Acquired | (price as of 2026-10-02) |
| May 3, 2016 | PCRX | A | 40,000 | · | · | 40,000 Direct | · | Acquired | (price as of 2026-10-02) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| June 14, 2017 | PCRX | Stock Option (Right to Buy) | Common Stock | $44.20 | June 14, 2027 | 9,000 | Acquired |
| Dec. 7, 2016 | PCRX | Stock Option (Right to Buy) | Common Stock | $32.35 | Dec. 7, 2026 | 16,000 | Acquired |
| June 15, 2016 | PCRX | Stock Option (Right to Buy) | Common Stock | $40.34 | June 15, 2026 | 10,000 | Acquired |
| May 3, 2016 | PCRX | Stock Option (Right to Buy) | Common Stock | $51.54 | May 3, 2026 | 40,000 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2016 | $270,385 | $86,000 | · | $1,470,114 | · | · | $98,079 | $1,924,578 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.